A study has found that people with terminal lung or skin cancers lived twice as long if they received immunotherapy drugs - at the start of the day instead of after lunchtime.
Researchers believe the immune system is more active earlier in the dayGiving cancer patients immunotherapy early in the morning rather than in the afternoon could improve survival rates.
Previous studies found there are higher levels of immune cells circulating in the blood in the early morning. Since 2011 when the first immunotherapy drugs were licensed in the UK for the treatment of malignant melanoma , average survival time has risen from six months to five years or more. The theory is that giving immunotherapy at the start of the day would supercharge this response, as there are more T-cells circulating then.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Scientists pioneer immunotherapy technique for autoimmune diseasesMayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.
Read more »
Soluble Immune Checkpoint Factors in Blood as Potential Biomarkers for ICI Cancer ImmunotherapyResearchers have identified soluble immune checkpoint factors in the blood that can be used as potential biomarkers to assess the efficacy of cancer immunotherapy with immune checkpoint inhibitors (ICIs). This finding could have significant implications for personalized cancer treatment.
Read more »
A New Hope in Immunotherapy Against CancerResearchers have discovered a potential target for immunotherapy that could enhance the immune system's ability to fight cancer cells.
Read more »
Immunotherapy for Alzheimer's disease shows promise in mouse studyAlzheimer's disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline.
Read more »
Study finds immunotherapy combination before surgery improves outcomes for patients with pancreatic cancerA pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.
Read more »
Novel ADC and immunotherapy combo shows promise in endometrial cancer subtypeIn a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Read more »